Trial reportBone marrow transplantation2004
Outcomes of unrelated cord blood transplantation in pediatric recipients.
Trial report in Bone marrow transplantation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00008164 (Transplantation Using Umbilical Cord And Placental Blood), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transplantation Using Umbilical Cord And Placental Blood
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The complications of irradiation or busulfan for CAYA before hematopoietic stem cell transplantation: a systematic review and meta-analysis.Frontiers in pediatrics · 2026Pooled it
- High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.Transfusion · 2009Trial
- Neonatal factors impacting umbilical cord blood unit characteristics.Scientific reports · 2025Article
- Innovations in cell therapy in pediatric diseases: a narrative review.Translational pediatrics · 2023Review
- Unrelated donor α/β T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia.Blood advances · 2022Article
- Immunophenotypic, cytotoxic, proteomic and genomic characterization of human cord blood vs. peripheral blood CD56Innate immunity · 2019Article
- Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.Bone marrow transplantation · 2017Article
- Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients.Bone marrow transplantation · 2016Review
- A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.British journal of haematology · 2011Article
- Unrelated umbilical cord blood transplantation and immune reconstitution.Seminars in hematology · 2010Review
- Outcome following unrelated cord blood transplant in 136 patients with malignant and non-malignant diseases: a report from the Australian and New Zealand children's haematology and oncology group.Bone marrow transplantation · 2009Article
- Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases.Bone marrow transplantation · 2007Article
- Stem cell therapy for autism.Journal of translational medicine · 2007Review
- Successful unrelated umbilical cord blood transplantation in children with Shwachman-Diamond syndrome.Bone marrow transplantation · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report results of unrelated cord blood transplants (UCBT) in 29 pediatric recipients in one center and the risk factors associated with survival. Median age: 9 years (0.5-20); diagnosis: ALL (9), AML (4), CML (1), HD (3), HLH (1), NHL (3), NBL (2); B-thal (1), FA (1), FEL (1), Krabbe (1), WAS (1), SAA (1); median follow-up: 11 months; conditioning: total body irradiation (TBI)-ablative (14), chemotherapy-ablative (6) and reduced intensity chemotherapy (9); GVHD prophylaxis: MMF/FK506 (18), cyclosporin A (CsA)+steroids+/-MMF (7) or CsA+methotrexate (MTX) (4); median total nucleated cells (TNC): 3.8 x 10(7)/kg (1.1-11); median CD34+: 2.3 x 10(5)/kg (0.2-9.9); and HLA match: 2 (6/6), 5 (5/6), 22 (4/6). Neutrophil engraftment by cumulative incidence curves 63% (median 28 (95% confidence interval (CI) 18-32)). Probability of >/=grade II acute graft-versus-host disease (aGVHD) by day +60 27%, >/=grade III aGVHD 20% and chronic graft-versus-host disease 3%. Estimated 1-year overall survival (OS) 46% (95% CI 30-71) and standard risk 60% (95% CI 29-100%). Variables associated with improved survival by multivariate analysis include non-TBI-ablative conditioning (P=0.024), CD34+/kg (P=0.038) and gender (P=0.048). These results suggest that CD34/kg cell dose and non-TBI-ablative conditioning may be important variables influencing OS following UCBT in pediatric recipients. Given the small number of patients, these results should be viewed cautiously.
Indexed as
Identifiers
15107815What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.